Search

2025 JAN 25 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on antineoplastics are presented in a new report. According to [...]

2024 SEP 28 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on antineoplastics. According to news reporting out of [...]

2024 JUN 22 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on acne vulgaris have been presented. According to news reporting [...]

2024 JUN 20 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- New research on antineoplastics is the subject of a new report. According to news [...]

2024 FEB 17 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on neuroblastomas are presented in a new report. According to [...]

During 2 days of hearings on potential modifications to the isotretinoin iPLEDGE Risk Evaluation and Mitigation Strategy, there was much agreement among dermatologists, industry representatives, and Food and Drug Administration [...]

A recent study conducted by Harvard Medical School focused on acne relapse and isotretinoin retrial in patients with acne. The research aimed to identify factors influencing acne relapse and retrial rates among patients who received isotretinoin treatment. The study found that higher cumulative dosage of isotretinoin may potentially reduce the risk of acne relapse and retrial, while daily dosing could be individualized based on patient goals and preferences. This peer-reviewed research provides valuable insights for healthcare professionals and patients dealing with acne treatment. [Extracted from the article]

Researchers at Kuban State Medical University have conducted a study on the recurrence of acne after treatment with systemic isotretinoin, focusing on the causes and methods of prevention. The study emphasizes the importance of a personalized approach to managing patients with acne to increase the effectiveness of isotretinoin therapy and reduce the likelihood of disease progression. The research highlights the multifactorial nature of acne development and the need to consider individual patient characteristics in treatment strategies. [Extracted from the article]

A recent study conducted at Stanford University investigated the effectiveness of isotretinoin administration in patients with thick nasal skin undergoing rhinoplasty. The study reviewed various research studies and found that while some demonstrated an improvement in aesthetic satisfaction postoperatively, inconsistencies in treatment protocols and outcome measures made it challenging to determine the overall effectiveness of isotretinoin in rhinoplasty. The research concluded that more standardized protocols and long-term follow-up studies are needed to assess the true impact of isotretinoin in rhinoplasty procedures. [Extracted from the article]

A study conducted by the University of Auckland evaluated the impact of widening access to isotretinoin for acne treatment in New Zealand from 2008 to 2023. The research found that expanding access to primary care clinicians resulted in a significant increase in prescriptions, with primary care now issuing the majority of isotretinoin prescriptions. The study also highlighted a reduction in ethnic disparities in access to isotretinoin, with prescriptions for Maori and Asian patients increasing at a faster rate compared to Europeans. This research suggests that with appropriate education and support, primary care providers can safely deliver equitable access to isotretinoin for acne treatment. [Extracted from the article]

A study conducted by researchers at Mass General Brigham found that approximately 1-in-5 patients experience acne recurrence after taking isotretinoin for severe acne, with females and those who had taken lower cumulative dosages being at higher risk. The study, published in JAMA Dermatology, suggests that dosing regimens could be individualized based on patient goals and preferences, as both lower and higher daily dose regimens can be effective as long as a sufficient cumulative dose is reached. The researchers also found that greater cumulative isotretinoin dose was associated with reduced acne recurrence, but not beyond 220mg/kg. [Extracted from the article]

A recent report from Tshwane University of Technology discusses the misuse of isotretinoin in South Africa, a potent retinoid drug primarily used for severe acne treatment. The research explores the epidemiological trends, motivations, health risks, and sociocultural factors contributing to the abuse of isotretinoin. While the drug remains valuable for acne management, the study emphasizes the need for comprehensive approaches involving healthcare professionals, policymakers, and the public to ensure safe and appropriate use through rational medicine interventions. [Extracted from the article]

A recent study conducted by the Department of Dermatology focused on epidermolytic ichthyosis (EI), a rare skin condition affecting 1 in 200,000-300,000 individuals worldwide. The study highlighted the significant improvement in clinical outcomes and quality of life for a 27-year-old Filipino male with EI, who was treated with hydration, lubrication, keratolysis, and low-dose isotretinoin. The research concluded that oral isotretinoin showed efficacy in treating EI, leading to improvements in cosmetic and functional capacity, as well as overall quality of life for the patient. [Extracted from the article]

A recent study conducted at Cheikh Anta Diop University of Dakar focused on antenatal imaging of retinoic acid embryofetopathy, specifically related to isotretinoin exposure during pregnancy. The research highlighted the identification of pulmonary valve agenesis as a new malformation associated with isotretinoin exposure, expanding the known spectrum of related abnormalities. The study emphasized the importance of investigating isotretinoin exposure in cases of conotruncal heart defects without 22q11 deletion. For more information, the full article can be accessed through the Journal of Case Reports and Images in Obstetrics and Gynecology. [Extracted from the article]

An infant girl underwent treatment for an embryonal tumor with multilayered rosettes, receiving a combination of chemotherapy drugs and stem cell transplants. Despite achieving sustained remission, she experienced various toxicities such as mucositis, febrile neutropenia, pseudomonas sepsis, and epistaxis as side effects of the treatment. The girl required intensive care, including intubation, due to respiratory arrest caused by complications from the therapy. [Extracted from the article]

The article discusses two case reports of teenage boys with acne fulminans who experienced various toxicities and drug ineffectiveness while being treated with doxycycline, isotretinoin, and prednisone. Patient 1, a 17-year-old boy, did not respond well to isotretinoin and prednisone, experiencing adverse effects, but showed improvement with fluorescent light energy therapy. Patient 2, a 16-year-old boy, had a flare-up of acne fulminans while on isotretinoin, leading to discontinuation of the drug and subsequent treatment with azithromycin and prednisone, resulting in clinical recovery. [Extracted from the article]

The US Food and Drug Administration (FDA) agreed to require important American Academy of Dermatology's (AAD) recommended changes to the iPLEDGE programme that will alleviate administrative burdens for dermatologists. 'Because [...]

The Food and Drug Administration (FDA) is requiring manufacturers make changes to the iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) program for https://www.empr.com/generic-drug/isotretinoin/ to help reduce the administrative burden on [...]

TORONTO -- Dermatologists should prescribe emergency contraception (EC) to adolescent patients being treated with isotretinoin for acne. That was one of the main messages from Andrea L. Zaenglein, MD, professor [...]

After years of debate and disagreement, could an improved, more user-friendly version of iPLEDGE be on the horizon? iPLEDGE, the Food and Drug Administration (FDA)-required Risk Evaluation and Mitigation Strategy [...]

ISOTRETINOIN WAS EFFECTIVE in treating acne in individuals undergoing masculinizing gender-affirming hormone therapy in a case series. The effectiveness and safety of isotretinoin in transgender and gender-diverse individuals are not [...]

Isotretinoin was not associated with a 1-year risk of incident inflammatory bowel disease in a large population-based cohort study that also found no significant association of oral tetracycline-class antibiotics with [...]

When it comes to managing acne, new guidelines from the American Academy of Dermatology (AAD) rate the existing evidence as 'strong' for topical benzoyl peroxide, retinoids, and / or antibiotics [...]

When it comes to managing acne, new guidelines from the American Academy of Dermatology rate the existing evidence as 'strong' for topical benzoyl peroxide, retinoids, and/or antibiotics and their fixed-dose [...]

Myo-inositol promotes the entry of glucose into the cell and is a safe and often effective supplement to recommend for acne, particularly for those patients who do not want traditional [...]

ISOTRETINOIN USERS have no increased risk of suicide or psychiatric conditions on a population level, a meta-analysis of 25 studies that included 1.6 million patients suggests. Instead, those who are [...]

In a letter dated Nov. 30, 2023, the Food and Drug Administration (FDA) informed isotretinoin manufacturers that they have 6 months to make five changes to existing iPLEDGE Risk Evaluation [...]

More than 3 months after the U.S. Supreme Court ruled in Dobbs v. Jackson Women's Health Organization that the Constitution does not confer the right to an abortion, dermatologists who [...]

A recent study from Safdarjung Hospital in New Delhi, India, focused on a case of periungual pyogenic granuloma in multiple nails due to isotretinoin use. The study highlighted the importance of recognizing and promptly addressing rare adverse events associated with medication errors, emphasizing the significance of timely intervention and appropriate management strategies. The research delved into potential mechanisms linking isotretinoin to increased skin fragility and granulation tissue development, providing insights from experts in the field. [Extracted from the article]

A study conducted at Fethi Sekin City Hospital explored the relationship between serum lipid levels, psychiatric symptoms, and suicidal ideation in acne patients undergoing isotretinoin therapy. The research found significant correlations between lipid parameters and suicidal ideation, depression, and anxiety scores. The study suggests that serum lipid levels may serve as indicators of psychiatric side effects in patients on isotretinoin therapy, but further research with larger sample sizes is needed to confirm these findings. [Extracted from the article]

A recent study from the Department of Biomedicine examined the skin microbiome in acne vulgaris patients before and after isotretinoin treatment. The research found a decrease in Cutibacterium acnes and an increase in staphylococci in the acne microbiome, suggesting a potential role of staphylococci in acne pathophysiology. Isotretinoin treatment significantly reduced C. acnes and staphylococci, but also led to an increase in harmful bacteria like Staphylococcus aureus, indicating the need for post-treatment strategies to promote skin microbiome recovery. The study was published in JEADV Clinical Practice and can be accessed for free online. [Extracted from the article]

Research from Chongqing Hospital of Traditional Chinese Medicine discusses the successful treatment of Follicular occlusion triad (FOT) using adalimumab combined with isotretinoin. The study also reviews current research progress on biologic therapies for FOT, highlighting the effectiveness of adalimumab and secukinumab. Biologic therapies have significantly improved FOT management for patients who do not respond to conventional treatments, with ongoing advancements expected in this field. [Extracted from the article]

A study conducted at the University of Jordan focused on acne vulgaris and the use of isotretinoin as a treatment. The research analyzed laboratory abnormalities and changes in inflammatory parameters in 1182 patients over a five-year period. The study found that a baseline cholesterol level of 163.9 mg/dl and a baseline triglycerides level of 85.5 mg/dL were effective in detecting grade 1 abnormalities in patients receiving isotretinoin. This novel predictive method could serve as an effective risk stratification tool for acne patients undergoing isotretinoin treatment. [Extracted from the article]

The article discusses a systematic review on the outcomes and adverse effects of isotretinoin in acne treatment conducted by researchers at Cardinal Stefan Wyszynski University in Warsaw. Isotretinoin, a drug used for moderate to severe acne that is unresponsive to other treatments, is highlighted for its effectiveness in preventing physical scarring and psychological impacts associated with severe acne. The review emphasizes the importance of careful patient management due to isotretinoin's teratogenic nature, particularly for women of reproductive age who must use contraception during treatment. The research underscores the drug's inhibitory effect on sebaceous gland activity and proliferation, while cautioning about potential side effects across various body systems. [Extracted from the article]

A clinical trial, NCT06698263, is being conducted to assess the impact of weekly isotretinoin administration on sperm production in men with oligozoospermia. Participants will be randomly assigned to receive either isotretinoin or a placebo, with the primary outcome being changes in sperm production over a 20-week treatment period. The study aims to determine if isotretinoin can stimulate spermatogenesis and improve sperm count in infertile men. [Extracted from the article]

A study conducted by Xiamen University in Fujian, China, analyzed adverse drug reactions related to dry eye using data from the FDA Adverse Event Reporting System. The research identified 33 drugs with significant risk of causing dry eye, with isotretinoin, tisotumab vedotin, and brimonidine being the top three. The study highlighted the importance of informed clinical decision-making to prevent drug-related dry eye, especially among females and elderly individuals. This research aims to optimize treatment and provide cautionary information regarding the risk of dry eyes associated with various medications. [Extracted from the article]

A case report published in Reactions Weekly in 2024 discusses a 45-year-old man who developed progressive cervical osteophytosis and dysphagia while undergoing treatment with isotretinoin for rosacea. The man had a history of various medical conditions and had been taking isotretinoin for approximately 13 years. After being diagnosed with progressive cervical osteophytosis and dysphagia, his isotretinoin therapy was discontinued, and he underwent surgery for dysphagia and excision of cervical osteophytosis. The case study highlights a potential association between long-term isotretinoin therapy and these adverse effects. [Extracted from the article]

The article discusses two case reports of infants who developed congenital malformations, specifically hydrocephalus and biliary obstruction, after in-utero exposure to isotretinoin. The mothers of these infants were receiving isotretinoin for acne treatment during pregnancy. The study highlights the potential risks associated with isotretinoin exposure during pregnancy, emphasizing the importance of caution and awareness in such cases. [Extracted from the article]

A recent study conducted at the University of Tennessee Health Science Center focused on isotretinoin, a form of Vitamin A used to treat severe acne vulgaris. The research highlighted the unique physical and mental side effects experienced by patients on isotretinoin, emphasizing the importance of patient-provider shared decision-making and open dialogue about side effects during monthly visits. The study recommended that dermatologists should present all treatment options to patients and consider creating a systematic documentation of symptoms to guide treatment plans. [Extracted from the article]

Researchers at Bagcilar Training and Research Hospital conducted a study on nail changes in patients receiving systemic isotretinoin therapy for acne vulgaris. The study included 200 patients, with 100 receiving isotretinoin treatment and 100 receiving topical acne treatment. The research found that isotretinoin increased the risk of nail changes, with onychoschizia being the most common change observed. The study concluded that the risk of developing nail changes was associated with the total cumulative dose of isotretinoin and that the changes were reversible. [Extracted from the article]

The research conducted at George Washington University explores the potential of Isotretinoin, an FDA-approved compound, in promoting the elimination of translation-competent HIV latent reservoirs in CD4T cells. By enhancing the ability of IL-15 to reactivate latent reservoirs and sensitizing reactivated cells to apoptosis, Isotretinoin shows promise as a novel approach to target and eliminate HIV reservoirs. The study suggests that Isotretinoin could be used in combinatorial strategies towards the development of an HIV cure by reducing latent reservoirs. [Extracted from the article]

Researchers at Universidad Autonoma de Bucaramanga conducted a study on the use of isotretinoin and its potential link to inflammatory bowel disease (IBD). While isotretinoin is effective in treating severe acne, concerns have been raised about its association with IBD. The study found a lack of substantial scientific evidence supporting a causal relationship between isotretinoin use and the development of IBD. For more information, readers can refer to the article "The use of isotretinoin increases the risk of inflammatory bowel disease. A narrative review" published in the Iberoamerican Journal of Medicine. [Extracted from the article]

The article discusses the importance of psychological follow-up in rhinoplasty, specifically focusing on the use of isotretinoin as a skin preparation agent. Research suggests that while isotretinoin has beneficial effects on skin preparation, its continuous use before rhinoplasty may interfere with healing and increase the risk of hematological changes. The decision to use isotretinoin should be individualized, taking into account the surgeon's experience, patient characteristics, and balancing aesthetic benefits with potential risks. A collaborative approach between plastic surgeons, dermatologists, and patients is essential for safe and effective use of isotretinoin in rhinoplasty. [Extracted from the article]

A 4-year-old boy with stage IV neuroblastoma experienced an anaphylactic reaction during immunotherapy with dinutuximab and showed lack of efficacy with isotretinoin treatment. After undergoing chemotherapy, tumor removal, and bone marrow transplantation, he faced complications during immunotherapy and isotretinoin cycles. Subsequent treatments included chemotherapy, tumor removal, bone marrow transplantation, and immunotherapy with dinutuximab, which were completed without serious complications. [Extracted from the article]

Researchers from George Washington University conducted a study on the readability of the iPLEDGE Comprehension Assessment (iPCA) used in the treatment of severe nodular acne with isotretinoin. The study found that the language complexity of the iPCA may hinder patient comprehension, leading to delays and potential discontinuation of treatment, especially among female patients. The researchers suggest that simplifying the iPCA could improve patient safety, comprehension, and access to isotretinoin, despite a decrease in isotretinoin-exposed pregnancies since the inception of iPLEDGE regulations. [Extracted from the article]

Researchers at University Hospital Basel published a case report on a patient with Acute Promyelocytic Leukemia (APL) who was treated with isotretinoin instead of the standard therapy of all-trans retinoic acid (ATRA) in combination with arsenic trioxide (ATO). Despite a prescription error, the patient achieved stable complete remission, suggesting that isotretinoin could be effective in treating APL. The study highlights the potential of isotretinoin as a treatment option for APL, offering new insights into alternative therapies for this type of leukemia. [Extracted from the article]

A recent review conducted by researchers from Lazarski University in Warsaw, Poland, examines the relationship between isotretinoin, a vitamin A derivative used to treat severe acne, and the development of depression in patients undergoing treatment. Isotretinoin is known for its effectiveness in treating acne, but it is also associated with adverse effects, including psychiatric disorders such as depression. The review aims to critically examine existing research to clarify the potential risks of depression associated with isotretinoin use. The full article can be accessed for free through the provided link. [Extracted from the article]

A recent study from Rutgers University Robert Wood Johnson Medical School explores the relationship between acne and the cutaneous microbiome. The study aims to assess the effects of current acne treatments on the microbiome and explore implications for developing new therapies. The research found that the cutaneous microbiome plays a complex role in acne pathogenesis, with certain bacteria contributing to inflammation and dysbiosis. The study also highlights the potential of newer therapies, such as probiotics and plant extracts, to restore microbial balance. The findings emphasize the need for personalized approaches to acne management based on microbiome modulation. [Extracted from the article]

A recent report from the University of Colorado Anschutz Medical Campus discusses the findings of a study on acne fulminans (AF), a severe form of inflammatory acne commonly found in adolescents. AF is characterized by painful nodules and plaques that can progress to suppurative, ulcerative, and hemorrhagic lesions. The exact cause of AF is unknown, but it has been linked to certain medications and autoinflammatory syndromes. The most common presentation of AF is seen in adolescents starting isotretinoin therapy. The main treatment for AF is a combination of prednisone and isotretinoin, and early identification and treatment are crucial to minimize symptoms and scarring. Further research is needed to determine optimal management. [Extracted from the article]

A recent study conducted by researchers at the University of Warmia and Mazury in Olsztyn, Poland, aimed to evaluate the impact of lifestyle patterns on the occurrence and severity of adverse events (AEs) in patients with acne undergoing isotretinoin therapy. The study found that lifestyle factors such as physical activity, smoking, and eating habits did not affect the incidence and severity of AEs, indicating the safety of isotretinoin regardless of unhealthy habits. The researchers concluded that isotretinoin remains the most effective drug for acne treatment and should not be abandoned despite the AEs. This research has been peer-reviewed. [Extracted from the article]